QLIFE HOLDING AB, Interim Report Q4, January to December 2022
Preparing for product launchFinancial summary – fourth quarter 2022 · Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test activities in Qlife’s markets remain very low. · EBITDA for the period amounted to kSEK -16,843 (-11,769), and net loss kSEK -25,413 (-13,075). · The total cash flow in the third quarter amounted to kSEK 3,180 (-9,307). Cash flow from the share issue in October was MSEK 43 and amortization of bridge loans in the quarter -24 MSEK. Tax credit regarding 2021 was paid out in